← All FDA warning letters

FDA Warning Letter · #728293

RoenRx — FDA Warning Letter (June 8, 2026)

Legal name: Roen Health, Inc.

Issued June 8, 2026Status: activeCenter for Drug Evaluation and Research (CDER)

In plain English

Marketing claims

FDA reviewed RoenRx’s website and said its marketing of compounded semaglutide products was false or misleading. FDA says the site’s claims suggested the products were FDA-approved or reviewed for safety and effectiveness, which compounded drugs are not.

What it means for you

This letter is about how the products were advertised. It is not a finding that a specific product or batch was contaminated or unsafe. Compounded GLP-1s are not FDA-approved, so if you use this company, ask which pharmacy makes your medication.

Drugs named:semaglutideOur Roen Rx review →

Primary Source

View the original FDA letter on fda.gov →

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/roen-health-inc-dba-roenrx-728293-06082026

Letter details

Company
Roen Health, Inc. (dba RoenRx)
Letter number
#728293
Issue date
June 8, 2026
Subject
False & Misleading Claims/Misbranded (Telehealth)

What FDA cited

Violations were identified and documented during a review of RoenRx’s website, https://roenrx.com, FDA Establishment Identifier (FEI) 3044022969, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide products. … Your representations regarding compounded semaglutide products are false or misleading.

From the letter

Read full letter on FDA.gov →

Quoted verbatim from the FDA warning letter dated June 8, 2026

Violations were identified and documented during a review of RoenRx’s website, https://roenrx.com, FDA Establishment Identifier (FEI) 3044022969, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide products. As described below, your website’s false or misleading claims concerning compounded semaglutide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.

Your representations regarding compounded semaglutide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.

1. The compounded semaglutide products displayed on your website identify “RoenRx” on the pictured label, suggesting RoenRx is the compounder of those drugs when in fact it is not.

2. The following claims concerning compounded semaglutide products appear on your website: “Semaglutide is the active ingredient in FDA-approved medications like Wegovy and Ozempic….” “RoenRx also offers semaglutide, the active ingredient in Wegovy® and Ozempic®….” “Get affordable semaglutide (main ingredient in Ozempic® & Wegovy®) at an affordable price.”

Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.

Source: U.S. Food and Drug Administration. Quoted as a verbatim excerpt for editorial commentary; no claim is made beyond what FDA itself has published. The full letter is available at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/roen-health-inc-dba-roenrx-728293-06082026

What FDA warning letters mean

A warning letter is FDA's principal means of telling a company that the agency considers something it's doing — a marketing claim, a manufacturing practice, a labeling choice — to violate the Federal Food, Drug, and Cosmetic Act. Companies typically have 15 working days to respond.

A warning letter is not a recall, a criminal charge, or a finding that the company has broken the law. It is the start of a regulatory conversation. FDA may issue a close-out letter once it is satisfied that the company has corrected the cited issues.

For compounded GLP-1 telehealth providers, the most common citations involve unapproved new drug claims, misbranding, and the use of bulk drug substances not on FDA's approved list under FDCA sections 503A and 503B.

What this letter means if you use compounded GLP-1s

A warning letter is not a recall, and it does not by itself mean a product you already have is unsafe, but it does mean the FDA found problems it expects RoenRx to fix. Compounded GLP-1s are not FDA-approved, and the rules for selling them changed when the shortages ended; our explainer on where compounded semaglutide stands with the FDA now covers what is still allowed. How Roen Rx handles care and pricing today is in our review of Roen Rx.

Advertising is the subject of this letter, so it helps to know what the approved products are. Our semaglutide overview page lists the brand-name versions FDA has reviewed, and our patient guide to compounded versus brand-name GLP-1s walks through the trade-offs between the two.

Other warning letters in our database

View the full database →

Editorial Disclaimer

FDA warning letters are public regulatory communications and do not, on their own, indicate that a company has done anything illegal. Companies often respond to warning letters with corrective action, and many letters are eventually closed out. The full text of this letter is available on fda.gov via the link above.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.